SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2586SQNM -20% after hours SAN DIEGO (AP) -- Diagnostic test maker Sequenom Inc. on Mtnsaf-3/15/2010
2585MNKD: Feuerstein worries about PR wording; maybe best to wait until the CC tomotuck-3/15/2010
2584MannKind (MNKD) off 23% on receipt of CRL. No clinical or preclinical trials astuck-3/15/2010
2582CYTX - and a follow-on 16% today.tom pope-3/15/2010
2581Having a brand name means nothing. For ANX to issue such a PR is cheesy, IMO.DewDiligence_on_SI-3/12/2010
2580Cytori (CYTX): Bigger than expected loss has the stock down around 17%. Over retuck-3/12/2010
2579ANX is approved for its exelbine brand name for 530 : ADVENTRX Receives Brand Namlkr-3/12/2010
2578GEN.CO -20% Genmab Announces Results From Zalutumumab Phase III Study of Refracttnsaf-3/9/2010
2577DEPO: 2.83 now.. must have been due to short squeeze?mlkr-3/3/2010
2576MDVN: Biotech "magazine's" report : 1. Medivation's Dimebon famlkr-3/3/2010
2575Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrmlkr-3/3/2010
2574Is that a question?DewDiligence_on_SI-3/3/2010
2573MDVN down $27 to $13? Medivation tumbles on Dimebon trial failure Medivation lomlkr-3/3/2010
2572NVLT: Anyone getting in?mlkr-3/3/2010
2571But there is also 514 to be filled during may 2010 according to their CC. May lemlkr-3/3/2010
2570ANX gets FDA Refusal-To-File letter for ANX-530: finance.yahoo.com CC today (MDewDiligence_on_SI-3/1/2010
2569Novelos (NVLT.OB) off 81% on failure in P3 lung cancer trial: >>Novelos Ttuck-2/24/2010
2568Thanks for posting, once more I see the cockroach theory proven... if there is RockyBalboa-2/22/2010
2567DEPO down 25 percent to 2.30; XNPT down initially 66 percent to 7.03-6.50. Startmlkr-2/20/2010
2566ARYx 1.61 now and lets see where "strategic" soul searching will lead mlkr-2/19/2010
2565Charity <i>pick</i>, or charity <i>case</i>? :-)DewDiligence_on_SI-2/19/2010
2564Aryx pummeled again after company gives up on partnering its other late stage drtuck-2/19/2010
2563Looking backwards, yes. Looking forward RBC with an OUTPERFORM reiterated and aIan@SI-2/18/2010
2562I guess of the seven, Citigroup wins the award even though their target was $20 rkrw-2/18/2010
25617 and counting... <pre> Company Symbol Brokerage Firm Action Ratings ChanIan@SI-2/18/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News